Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 28;384(4):335-344.
doi: 10.1056/NEJMoa2022141.

Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception

Affiliations
Randomized Controlled Trial

Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception

David K Turok et al. N Engl J Med. .

Abstract

Background: In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception. Currently, clinicians offer only copper IUDs for emergency contraception because data are lacking on the efficacy of the levonorgestrel IUD for this purpose.

Methods: This randomized noninferiority trial, in which participants were unaware of the group assignments, was conducted at six clinics in Utah and included women who sought emergency contraception after at least one episode of unprotected intercourse within 5 days before presentation and agreed to placement of an IUD. We randomly assigned participants in a 1:1 ratio to receive a levonorgestrel 52-mg IUD or a copper T380A IUD. The primary outcome was a positive urine pregnancy test 1 month after IUD insertion. When a 1-month urine pregnancy test was unavailable, we used survey and health record data to determine pregnancy status. The prespecified noninferiority margin was 2.5 percentage points.

Results: Among the 355 participants randomly assigned to receive levonorgestrel IUDs and 356 assigned to receive copper IUDs, 317 and 321, respectively, received the interventions and provided 1-month outcome data. Of these, 290 in the levonorgestrel group and 300 in the copper IUD group had a 1-month urine pregnancy test. In the modified intention-to-treat and per-protocol analyses, pregnancy rates were 1 in 317 (0.3%; 95% confidence interval [CI], 0.01 to 1.7) in the levonorgestrel group and 0 in 321 (0%; 95% CI, 0 to 1.1) in the copper IUD group; the between-group absolute difference in both analyses was 0.3 percentage points (95% CI, -0.9 to 1.8), consistent with the noninferiority of the levonorgestrel IUD to the copper IUD. Adverse events resulting in participants seeking medical care in the first month after IUD placement occurred in 5.2% of participants in the levonorgestrel IUD group and 4.9% of those in the copper IUD group.

Conclusions: The levonorgestrel IUD was noninferior to the copper IUD for emergency contraception. (Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov number, NCT02175030.).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Enrollment, Randomization, Follow-up, and Analysis.
Figure 2.
Figure 2.. One-Month Pregnancy Outcomes with the Levonorgestrel 52-mg IUD versus the Copper T380A IUD, According to Type of Analysis.
The primary outcome, a positive urine pregnancy test 1 month after IUD insertion, was designed to test the efficacy of the levonorgestrel (LNG) 52-mg IUD and copper T380 IUD for emergency contraception. Forty-eight participants did not provide urine pregnancy tests and had their pregnancy outcomes reported by survey and health record data. The modified intention-to-treat analysis includes all participants receiving an IUD who reported the 1-month pregnancy outcome by any method. The per-protocol analysis includes only participants who were still using the IUD to which they were randomly assigned when the 1-month pregnancy outcome was reported. The sensitivity analysis includes only participants with the 1-month pregnancy outcome confirmed by a urine pregnancy test. The Miettinen–Nurminen method was used to compute the two-sided 95% confidence interval around the proportion difference to test noninferiority.

References

    1. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012; 27: 1994–2000. - PMC - PubMed
    1. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555–62. - PubMed
    1. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803–10. - PubMed
    1. Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212(1): 50.e1–8. - PMC - PubMed
    1. Sanders JN, Myers K, Gawron LM, Simmons RG, Turok DK. Contraceptive method use during the community-wide HER Salt Lake contraceptive initiative. Am J Public Health 2018; 108: 550–6. - PMC - PubMed

Associated data